Rationale and design of the randomised controlled cross-over trial: Cardiovascular Effects of Empaglifozin in Diabetes Mellitus

Sharmaine A Thirunavukarasu (✉ sharmainethiru@gmail.com)
University of Leeds

Louise AE Brown
University of Leeds

Amrit Chowdhary
University of Leeds

Nicholas Jex
University of Leeds

Peter Swoboda
University of Leeds

John P. Greenwood
University of Leeds

Sven Plein
University of Leeds

Eylem Levelt
University of Leeds

Study protocol

Keywords: Empaglifozin, Cardiovascular magnetic resonance imaging, Type 2 diabetes (T2D), Continuous glucose monitoring (CGM)

Posted Date: March 4th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-262075/v1

License: ☄️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background** Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular (CV) disease. In patients with T2D and established CV disease, selective inhibitors of sodium–glucose cotransporter 2 (SGLT2) have been shown to decrease CV and all-cause mortality, and heart failure (HF) admissions. Utilising CV magnetic resonance imaging (CMR) and continuous glucose monitoring (CGM) by FreeStyle Libre Pro Sensor, we aim to explore the mechanisms of action which give Empagliflozin, an SGLT2 inhibitor, its beneficial CV effects and compare these to the effects of dipeptidyl peptidase-4 inhibitor Sitagliptin.

**Methods** This is a single centre, open-label, cross-over trial conducted at the Leeds Teaching Hospitals NHS Trust. Participants are randomised for the order of treatment and receive three months therapy with Empagliflozin, and three months therapy with Sitagliptin sequentially. Twenty eight eligible T2D patients with established ischemic heart disease will be recruited. Patients undergo serial CMR scans on 3 visits, at week 0, week 12 and week 24 of the study.

**Discussion** The primary outcome measure is the myocardial perfusion reserve in remote myocardium. The secondary outcome measures are myocardial fibrosis, ECV, aortic distensibility, LV/RV volume and function, and the relationship between glycemic markers and CV parameters.

We hypothesize that Empagliflozin treatment is associated with improvements in myocardial blood flow and reductions in myocardial interstitial fibrosis, independent of CGM measured glycemic control in patients with T2D and established CV disease.

**Trial registration** This study has full research ethics committee approval (REC: 18/YH/0190) and data collection is anticipated to finish in December 2021. This study was retrospectively registered at [https://doi.org/10.1186/ISRCTN82391603](https://doi.org/10.1186/ISRCTN82391603) and monitored by the University of Leeds. The study results will be submitted for publication within 6 months of completion.

**Background**

Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D)\(^1\). The cardiovascular effects of T2D are characterized by multiple interconnected mechanisms and involve the cardiomyocyte, fibroblast and endothelial cell (Figure 1). A significant breakthrough in contemporary cardiology was the finding that sodium–glucose-cotransporter-2 (SGLT2) inhibitors are associated with a lower risk of heart failure (HF) hospitalisation in patients with or at high risk of CV disease\(^2\). A selective inhibitor of SGLT2, Empagliflozin, reduces rates of hyperglycaemia in T2D patients by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion\(^3\). In addition, SGLT2 inhibition causes a modest rapid reduction in weight, hemoconcentration, and reduced blood pressure, consistent with a diuretic effect (2,3).
In the EMPAREG OUTCOME Trial, Empagliflozin reduced cardiovascular death and hospitalization for heart failure (HF) by 38% and 35%, respectively, with an almost immediate beneficial effect despite only a modest difference in glycaemic control, comparing two study arms over 94 weeks\(^2\). The reductions in CV death were not accounted for by the reductions in atherothrombotic outcomes, as the rates of myocardial infarction and stroke remained unchanged with therapy\(^2\). The proposed theory that HF is the outcome most sensitive to SGLT2 inhibition was confirmed in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program and Dapagliflozin DECLARE–TIMI 58 trials\(^4,5\). More recently, the EMPEROR trial showed that SGLT2 inhibition reduces the risk of hospitalization for HF in patients regardless of the presence or absence of diabetes\(^6\).

The mechanisms by which SGLT2 inhibitors cause the reduction in HF admissions and cardiovascular mortality are as yet unknown, however recently suggested theories include their impact on coronary microvascular function and pleiotropic anti-fibrotic effects\(^7\). Extensive evidence has documented the presence of coronary microvascular dysfunction \(^8,9\) \(^10-12\) and myocardial fibrosis \(^13-15\) in patients with T2D. Coronary microvascular dysfunction in diabetes is likely to be a multifactorial phenomenon, related to changes in perivascular and interstitial fibrosis \(^16\), myocardial hypertrophy \(^17\), reduced capillary density, and autonomic neuropathy \(^18\). Regarding the important drivers of interstitial fibrosis process in T2D, these include collagen cross-linking via accumulation of advanced glycation end-products, activation of inflammatory cytokines and potentiation of neurohormonal cascades such as upregulation of the renin–angiotensin–aldosterone system (RAAS) \(^19\). Importantly, both coronary microvascular dysfunction and interstitial fibrosis are both early precursors of cardiovascular events and were both shown to be associated with a 2-3 fold increased risk of annual major adverse event rate that includes cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and congestive HF even among patients without epicardial coronary artery stenosis \(^20,21\). The purpose of this study is to evaluate effects of SGLT2 inhibitor Empagliflozin on myocardial blood flow and myocardial interstitial fibrosis in patients with T2D.

**Cardiovascular magnetic resonance imaging in type 2 diabetes**

Cardiovascular magnetic resonance imaging (CMR) is the reference standard for assessment of cardiac volumes, mass and function and also allows assessment of ischaemia and fibrosis \(^28\). Using CMR, patients with T2D have been extensively phenotyped with a nuanced description of disease burden \(^14,29,30\). These studies have identified predictors of adverse CV events including distinct ventricular morphology \(^10,31\), reduced aortic distensibility \(^14,29,30\), impaired strain \(^12,14,30,32-34\), elevated myocardial extra cellular volume fraction indicating diffuse cardiac fibrosis \(^14\) and reduced myocardial perfusion \(^10,11\) in patients with T2D.

To our knowledge, the effects of Empagliflozin on myocardial perfusion, function, aortic distensibility and interstitial fibrosis has never been compared to other glucose lowering therapies. Similarly, antifibrotic properties of Empagliflozin compared with other agents remain to be shown in clinical studies of T2D. Optimizing glycaemic control alone has failed to improve short to medium term mortality but recent trials
of SGLT2 inhibitors provide new perspectives. Despite similar reductions in levels of glycaemia, only SGLT2 inhibitors and glucagon like peptide-1 receptor agonists improve CV outcomes, suggesting pleiotropic effects, potentially on myocardial fibrosis, aortic stiffness and myocardial perfusion effects.

**Continuous glucose monitoring- FreeStyle Libre Pro Sensor**

Continuous glucose monitoring (CGM) provides the advantage of measuring interstitial glucose every 5–15 minutes, thus providing a comprehensive 24-hour glycemic profile, with better assessment of nocturnal and/or asymptomatic hypoglycemia and pattern recognition after each treatment intervention\(^{20-25}\). Patients with T2D may experience hypoglycaemic events or increased glucose variability, both of which are linked to atherothrombotic vascular pathology and adverse clinical outcomes\(^{3;21;22;27;28}\).

Glycemic variability is considered an important glycemic target, together with glycosylated hemoglobin (HbA1c), to reduce the risk of diabetes complications. As this study aims to assess the cardiovascular beneficial effects of Empagliflozin independently of the drug's action on glucose levels, the FreeStyle Libre Pro Sensor will be used for reliable continuous monitoring of glucose levels.

**Methods/study Design**

**Participants, Interventions and Outcomes:** The CEED trial (Cardiovascular Effects of Empagliflozin in Diabetes Mellitus) is a single centre, open-label, randomized, cross-over study with blinded analysis of CMR data. The study has been registered at [https://doi.org/10.1186/ISRCTN82391603](https://doi.org/10.1186/ISRCTN82391603)

**Aims of the study:** The study is designed to determine the effects of Empagliflozin on cardiac structural and functional changes, perfusion and aortic distensibility in a population of patients with similar characteristics to those studied in recent clinical trials\(^{35}\) and compare them with the effects of Sitagliptin. Patients will be administered the two drugs sequentially. The study will involve physiological assessment including CMR imaging of biventricular volumes, function, quantitative adenosine stress perfusion imaging, myocardial extracellular fibrosis and aortic distensibility. Additionally, the impact of Empagliflozin and Sitagliptin on plasma glucose variability will also be assessed by FreeStyle Libre Pro Sensor\(^{36}\).

**Original Hypotheses:** Cardioprotective mechanisms of Empagliflozin include improvement of myocardial perfusion and aortic distensibility, and reduction in cardiac fibrosis in patients with T2D and established cardiovascular disease. These beneficial effects are independent of Empagliflozin's action on glucose levels.

**Justification of the hypothesised beneficial cardiovascular mechanisms and the mechanistic study:**

*SGLT2 inhibitors improve blood pressure and vascular function:* Significant BP reductions are detected after only 2 days of SGLT2 inhibition in T2D patients and SGLT2 inhibition almost immediately improves
systemic endothelial function and arterial stiffness\textsuperscript{37}.

\textbf{SGLT2 inhibitors have cardiac antifibrotic properties:} In the experimental work using human cardiac fibroblasts, Empagliflozin had direct effect on human cardiac fibroblast phenotype and function, particularly by attenuation of myofibroblast activity and cell-mediated collagen remodelling\textsuperscript{38}.

\textbf{Justification of the comparator glucose-lowering drug Sitagliptin:}

To test the CV beneficial effects of SGLT\textsuperscript{2} independently of the actions of the drug on glycemic control, it is important to compare SGLT\textsuperscript{2} treatment with a specific and clinically relevant treatment strategy, such as, dipeptidyl peptidase-4 (DPP-4) inhibitor therapy. The DPP-4 inhibitors belong to a class of widely used glucose lowering treatment for T2D, which have been shown to be associated with CV safety in large clinical trials\textsuperscript{39, 40}. As such, DPP-4 inhibitors are a well-suited comparator for examining the effectiveness of SGLT-2 inhibitors.

\textbf{Patient and Public Involvement}

We have worked closely with patients when developing this research and their voiced unmet needs have been pivotal in forming the research questions and study design. We have presented the study hypotheses and the proposed investigation methods, as well as their potential burden on the participants, to the Leeds Patient and Public Involvement (PPI) group and to the Leeds Diabetes UK Volunteer Group, and have incorporated the volunteers’ suggestions into the study protocol. In addition, Leeds PPI group with members of the public have reviewed all study documentation prior to application for ethics committee approval for the study protocol.

A Study Steering Committee, providing overall supervision of the study progress, adherence to protocol, participant safety and consideration of new information, includes a Patient Representative nominated by this PPI Volunteer group.

\textbf{Dissemination of research to the diabetes community}

In communicating the study results to as wide as possible an audience, special effort will be made to reach patients with type 2 diabetes, and people at risk of developing type 2 diabetes. One of the aims of the research is to raise greater awareness of the cardiovascular complications of diabetes and of possible preventative measures. We will take part in the Diabetes Wellness Days (drwf.org.uk/get-involved/diabetes-wellness-network), which bring together under one roof a wealth of information for people living with diabetes, their family members, carers, friends and those with an interest in the condition. These events will also provide information on the importance of supporting and taking part in research in this field. Work published in peer-reviewed journals will be shared with the press offices of the University where appropriate, whilst ensuring that results are presented to the media in an appropriate and accurate manner. Alongside press releases, we will pitch articles to The Conversation (theconversation.com/uk/health) – an online news website that partner’s researchers with journalists to
write about topical news stories – to explain our findings in greater depth, to a large, non-specialist, audience.

Finally, each participant will be given detailed feedback on their cardiac function and their glycaemic control respectively at the end of the study. The primary care physicians will receive a letter stating which drug had a better impact on improvement in glycaemic control after completion of the trial once the results are unblinded.

We are most grateful to the members of Leeds PPI group and Leeds Diabetes UK Volunteer Group for their contributions to design and recruitment process of this study.

Objectives and outcome measures:

**Primary objective:** To explore and compare the impact of Empagliflozin and Sitagliptin to modulate myocardial perfusion.

**Secondary objectives:** To explore and compare the impact of Empagliflozin and Sitagliptin on: i) Myocardial fibrosis; ii) myocardial function; iii) aortic distensibility; iv) plasma glucose variability (time in range, hypoglycaemic exposure, and glycaemic variability).

**Primary outcome measure:** Change in myocardial perfusion reserve in the remote territory.

**Secondary outcome measures:** After treatment change in: i) Myocardial extra cellular volume fraction (ECV); ii) myocardial perfusion reserve in the infarcted territory; iii) left ventricular ejection fraction, iv) right ventricular ejection fraction; v) left ventricular strain (peak circumferential systolic strain and peak early diastolic strain rate, and global longitudinal strain); vi) aortic distensibility; vii) Libre Pro FreeStyle Sensor measured parameters (TIR, hypoglycaemic exposure, and glycaemic variability).

Methods and Analysis

**Study Population:** Twenty-eight patients with underlying T2D and ischaemic heart disease will be recruited.

**Inclusion and exclusion criteria:**

Table 1. Inclusion and Exclusion Criteria
| Inclusion criteria | Exclusion criteria |
|-------------------|-------------------|
| · Diagnosis of T2D | · History of CABG or need for further revascularization |
| · Currently on Metformin as a single or dual therapy | · History of type 1 diabetes or previous diabetic ketoacidosis |
| · HbA1c >48 mmol/mol (>58mmol/mol if on a Sulphonylurea) within 3 months of recruitment | · Current treatment with Sitagliption or Empaglifozin |
| · Age between 18-84 years old | · Any absolute contraindication to CMR |
| · Ability to provide informed consent | · Contraindication to adenosine |
| · Prior diagnosis of ischaemic heart disease by angiography or a positive non-invasive stress test for ischaemia | · Severe asthma |

**CABG**, coronary artery bypass grafting; **CMR**, cardiac magnetic resonance; **eGFR**, estimated glomerular filtration rate; **T2D**, type 2 diabetes.

**Recruitment and data collection**: Patients will be recruited from the Leeds Teaching Hospitals NHS Trust (LTHT) or from GP practices. Participants will be identified from cardiology wards, cardiology clinics, and the cardiac rehabilitation clinics in LTHT. Suitable participants will be approached by a member of the clinical team and given a patient information sheet (PIS) if interested. Recruitment of T2D patients with no history of recent hospital admission is supported by the National Institute for Health Research Clinical Research Network (NIHR-CRN). NIHR-CRN team will approach GP surgeries with study information and practices which expressed interest in helping with recruitment to the CRN will become ‘patient identification centres’.

**STUDY INVESTIGATIONS**

Study flow chart, details of all study visits with assigned investigations and analysis techniques are provided in Figure 2. The assessments listed below will be carried out at each visit in the Advanced Imaging Centre at the Leeds General Infirmary.

**Informed consent**

Written informed consent will be taken from all patients.

**Blood tests**
Fasting bloods including glucose, serum insulin, C peptide, glycated hemoglobin (HbA1c), urea and electrolytes, kidney function tests and full blood count will be obtained.

**FreeStyle Libre Pro Sensor**

Glucose profile in the study participants will be studied in detail using FreeStyle Libre Pro Sensor. The FreeStyle Libre Pro Sensor is a blinded sensor worn for 14 days which takes a glucose measurement every 15 minutes (96 readings/day=total of 1344 glucose readings over 2 weeks). The FreeStyle Libre Pro Sensor allows measuring: i) time in range (TIR): time spent between 3.9 and 10.0 mmol/l/day (clinical target>70% in this range)\(^26\), ii) hypoglycaemic exposure: analysed at two levels as time spent at <3.9 mmol/l (target <4%) and <3.0 mmol/L (target <1%), in accordance with international guidelines \(^26\) and iii) glycaemic variability (GV): assessed as coefficient of variation (CoV, target <36%).

**Cardiovascular Magnetic Resonance**

Patients will undergo CMR studies at 3.0Tesla (Magnetom Prisma, Siemens, Germany) for determining structural, functional and ischemic changes in the heart (biventricular size, function, strain, aortic distensibility, myocardial perfusion, fibrosis and scarring). The scan will be repeated using the same CMR study protocol (Figure 3) after each treatment allocation. Cardiac imaging receiver coil configuration will be used, and electrocardiogram (ECG) gating will be performed.

CMR will include scout and cine imaging to assess LV volumes, mass and ejection fraction, myocardial strain parameters. For aortic distensibility measurements, high temporal resolution multi-phase SSFP cine imaging will be acquired transverse to the ascending and descending thoracic aorta at the level of the pulmonary artery bifurcation. Aortic pulse wave velocity will then be assessed using identical geometric planning with retrospectively gated, through-plane, phase-contrast velocity encoded images. Adenosine (140 \(\mu g/kg/min\)) will then be infused for at least 3 minutes. Subsequently, gadolinium-based contrast (Gadovist®, Bayer Pharma, Berlin, Germany) will be injected for first-pass perfusion imaging\(^41\). If the haemodynamic response was inadequate (HR increase < 10 bpm or systolic blood pressure decrease < 10 mmHg) then the infusion rate will be increased up to a maximum of 210 mcg/kg/min (maximal infusion duration 7 minutes). Adenosine will then be discontinued and, after at least 20 minutes to allow washout, another bolus of gadolinium (0.05 mmol/kg) will be given for rest perfusion imaging. Data acquisition will use a multi-slice, free-breathing, saturation recovery pulse sequence with fast low angle shot (FLASH) readout, acquired over 60 heartbeats. Late gadolinium enhancement (LGE) in matching LV short- and long-axis planes will be carried out more than 8 minutes after rest perfusion imaging. Postcontrast T1 mapping will then be carried out 15 minutes following the last contrast injection.

**Table 2.** CMR pulse sequence. LGE, late gadolinium enhancement, LV, left ventricular, RV, right ventricular, SA, short axis; LA, left atrium; PSIR, phase sensitive inversion recovery; MOCO, motion corrected; SSFP, steady-state free precession
| Major Components | LV, RV, LA size and function | Late Gadolinium Enhancement | T1-mapping | Perfusion |
|------------------|-----------------------------|-----------------------------|------------|-----------|
| **Preferred Pulse Sequence** | Fast gradient echo sequence; 10-12 slices; 30 phases; 10-12mm (free breathing with MOCO or breath holds of 5s) | PSIR MOCO SSFP (if not available, then PSIR without MOCO) | Native T1 mapping; 5s3s MOLLI; 3 slices (breath hold 11s) Post contrast T1; 4s3s2s MOLLI (breath hold 12s) | Kellman pixel-wise perfusion mapping T1 weighted saturation recovery prepared gradient echo sequence in 3-4 short axis slices; free breathing with MOCO |

**Cardiovascular Magnetic Resonance analysis**

All imaging will be analysed blinded to patient details. CMR data will be assessed quantitatively using commercially available software (CVI42, Circle Cardiovascular Imaging Inc, Calgary, Canada). Epicardial and endocardial borders will be traced offline on the LV cine stack at end-diastole and end-systole to calculate end-diastolic and end-systolic LV volumes, stroke volume, ejection fraction, and LV mass, as previously described\(^42\). Tissue tracking analysis will be performed using CVI42. The peak systolic circumferential strain, global longitudinal strain and diastolic strain rate data will be measured. Myocardial perfusion (MP) in ml/min/g will be assessed using in-line motion corrected perfusion mapping implemented within the Gadgetron software framework as described in\(^41\). Global (average myocardial perfusion for 16 segments) and segmental MP will be measured. MP reserve (MPR) will also be calculated defined as the ratio between MP at stress over rest. Focal and diffuse fibrosis will be assessed using LGE and native and post contrast T1 to estimate the myocardial ECV\(^43\). Aortic dimensions and aortic distensibility will be calculated by standard techniques\(^44\).

**Randomization**

Eligible patients will be randomized in a 1:1 ratio for the order in which they will receive Empagliflozin 10mg once daily and Sitagliptin 100mg once daily respectively. Participants will undergo randomisation at the baseline visit, using the randomisation schedule generated by the LTHT Clinical Trials team. Randomisations will be achieved using minimization incorporating a random element, via a computer-generated program, that will allocate patients in a 1:1 ratio after taking account of age, gender and BMI. Participants will be given labelled medication so they will be aware of which medication they are taking on each occasion. Instructions on how and when to take the prescribed medication in its licensed dose will be issued at the time of enrolment by the study investigators who are medically qualified and General Medical Council registered. There will be no washout period during this study which is recognised as a limitation of the study.
Monitoring

Recommended monitoring for both Empagliflozin and Sitagliptin is to check renal function prior to initiation and periodically throughout administration – stated as at least yearly for Empagliflozin and periodically for Sitagliptin. Accordingly, renal function tests will be tested prior to initiating medication and prior to each CMR scan; each visit, therefore prior to initiation and after 10 weeks of treatment (2-3 weeks before each scan). All participants will be fully informed about these potential side effects.

Statistics

Power calculations: With 28 participants, the study will have 80% power (binomial test) to show a change of 12% in myocardial blood flow$^{45}$.

Statistical analysis: Outcome measures at follow-up will be compared between groups using linear regression models, adjusted for baseline measures of the outcome. Differences between randomised groups will be tested overall, and then pairwise differences between groups will be estimated separately.

Planned subgroup analyses: Interaction tests within regression models will be used to formally test for differences in treatment effects between subgroups defined by age and sex, as secondary analyses. Any other subgroup analyses will be carried out in an exploratory, hypothesis-generating manner.

Compliance and loss to follow up: The participants will be free to withdraw from the study at any time. Where patients wish to withdraw from the study, clarification of the extent of withdrawal will be sought and documented in the case report form. Participants who withdraw from the study will not be replaced.

Potential risks and hazards: The safety of the treatment will be evaluated through collection of adverse events, with a particular focus on adverse events relevant to Empagliflozin and Sitagliptin. At the study completion/early termination visit, each patient will be instructed to report any subsequent adverse events that the patient’s GP believes could be related to the study drug treatment or study procedures. The patient information leaflets will include all adverse events considered relevant to treatment with Empagliflozin and Sitagliptin and to MR studies.

Identifying and reporting adverse events

Participants will be instructed to contact the investigators if any untoward events occur during the clinical study. This includes any unintentional, unfavourable clinical signs or symptoms, any new illnesses or disease, or deterioration of existing disease, and any clinically relevant deterioration in any laboratory assessments of clinical tests. All non-serious or expected adverse events will be recorded on the study CRF and will be reported to the main Research and Ethics Committee (REC).

In keeping with National Health Service Health Research Authority (HRA) guidelines, reports of Serious Adverse Events (SAEs) or Serious Adverse Reactions (SARs) that are related to the study and unexpected will be reported to the sponsor within 1 working day of the research team becoming aware of the event,
and submitted to the REC using the HRA Non-CTIMP safety report to REC form within 15 days of the chief investigator becoming aware of the event. Events will be followed up until the event has resolved or an outcome has been reached.

**Discussion**

Given recent findings on efficacy and benefits, SGLT2 inhibitors have rapidly established a significant role in the treatment of diabetes. In the EMPAREG OUTCOME Trial, in T2D patients both with and without a history of HF, Empagliflozin reduced hospitalisation for HF with almost immediate beneficial effect. SGLT2 inhibitors also cause a modest rapid reduction in weight, haemoconcentration, and reduced blood pressure, consistent with a diuretic effect, which could improve congestion\(^2,4,5\). Though SGLT2 inhibitors were initially developed to target hyperglycemia, given these beneficial effects reducing the risk of HF hospitalizations, SGLT2 inhibitors began to emerge as potential drugs to prevent HF in populations with and without diabetes\(^2,4,5\). While the mechanisms for the beneficial CV effects of SGLT2 inhibitors in T2D patients remain to be elucidated, the postulated mechanisms include: i) improvement in ventricular loading conditions through a reduction in preload with natriuresis and osmotic diuresis\(^46,47\), and afterload with reduction in BP and improvement in vascular function\(^37,48\); ii) restoration of cellular energy homeostasis by activation of AMP-activated protein kinase, inducing mild ketosis and inducing a metabolic switch toward utilisation of ketone bodies, fatty acids and branch chain amino acids\(^49,50\); iii) reduction of cardiac fibrosis; iv) alteration in adipokines, cytokine production and epicardial adipose tissue mass; v) significant reduction in LV mass\(^51\). Table 2 summarizes the details of recent clinical studies exploring the mechanisms for the beneficial CV effects of Empagliflozin. However, until definite answers are given, it appears that SGLT2 inhibitors exert their favourable HF outcome by pleiotropic mechanisms beyond the reduction of glucotoxicity and diuresis. This study aims to increase our understanding of the fundamental benefits of SGLT2 inhibition which could inspire a change in practice in the future either as an adjunct or as a first-line treatment for diabetes.

**Table 3.** Clinical studies exploring the mechanisms for the beneficial CV effects of Empagliflozin
| Study | Imaging modality | Journal/Year | Recruited cohort | Primary objective | Results |
|-------|-----------------|--------------|------------------|------------------|---------|
| Verma S., et al. | TTE before and 3 months after | Diabetes Care 2016 | 10 people with T2D and CVD | Change in LVSF and LV mass index | - Improved LV diastolic function according to early lateral e’<br> - Reduced LV mass index<br> - No difference in LV volumes and LV EF |
| Sakai T., et al. | TTE before and 3 months after | Circulation 2017 | 59 people with T2D and HFpEF | Assess improvement in vascular function and vascular structure in patients with HFpEF | - Improved LV diastolic function according to the E/A and E/e’ ratio |
| Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: A cardiac magnetic resonance study | Cardiac MRI before and 6 months after | Internal Medicine Journal 2019 | 25 people with T2D (17 drug and 8 placebo) | Assess cardiac functional and structural changes based on CMR measurements, | - Reduced LV end-diastolic volume<br> - No difference in LV mass, LV EF, atrial volumes and markers of cardiac fibrosis |
| Cohen N., et al. | | | | | |
| EMPA heart Cardio-link 6 trial | Cardiac MRI before and 6 months after | Circulation 2019 | 97 people with T2D and CVD (49 drug and 48 placebo) | 6-month change in LV mass indexed to body surface area from baseline as measured by cardiac magnetic resonance imaging | - Significant reduction in LV mass indexed to body surface area after 6 months<br> - No difference in LV EF and LV EF |
| Verma S., et al. | | | | | |
| Are the “Cardiac Benefits” of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4 EMPA-TROPISM) | Cardiac MRI before and 6 months after | JACC 2020 | 80 people with T2D and HFrEF | Change in LV end-systolic and end-diastolic volumes Change in LV EF | · Improvement in LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo |
| --- | --- | --- | --- | --- | --- |
| C. G. Santos-Gallego et al. | | | | |

| Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF) | Cardiac MRI before and 36 weeks after | Circulation 2020 | 105 patients with NYHA functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes | Changes from baseline to 36 weeks in LVESVi and LV GLS measured using cMRI | · Reduction in LV volumes in patients with HFrEF and type 2 diabetes or prediabetes |
| --- | --- | --- | --- | --- | --- |
| M.M.Y. Lee et al. | | | | |

A, mitral peak A-wave velocity; CVD, cardiovascular disease; E, mitral peak E-wave velocity; e’, early annular tissue Doppler velocity; EF, ejection fraction; HFrEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; MRI, magnetic resonance imaging; SGLT2, sodium-glucose cotransporter 2; T2D, type 2 diabetes; TTE, transthoracic echocardiography, cMRI, cardiac magnetic resonance imaging, LVESVI, LV end-systolic volume indexed to body surface area

**Declarations**

**Ethics approval and consent to participate**

Study Ethics approval was obtained from the Yorkshire and Humber – South Yorkshire Research Ethics Committee. This study has been funded by the British Heart Foundation following peer review of the grant application.

**Consent for publication**

Not applicable

**Availability of data and materials**
The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

None declared.

**Fundings**

This work was supported by the British Heart Foundation, grant number RG/16/1/32092.

**Authors contributions**

SP conceived the idea for the study. SP and LB designed the study protocol. EL, ST and SP drafted the manuscript. SP, EL designed the MRI protocol. All authors critically reviewed and approved the final draft of the manuscript.

**Acknowledgements**

Not applicable

**References**

1. Morrish JN, Wang SL, Stevens KL, Fuller HJ and Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. *Diabetologia*. 2001;44:S14-S21.
2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC and Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2015;373:2117-2128.
3. Cowie MR and Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. *Nature Reviews Cardiology*. 2020.
4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, Shaw W, Law G, Desai M and Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*. 2017;377:644-657.
5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M and Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2018;380:347-357.
6. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J,
Squire I, Taddei S, Wanner C and Zannad F. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *New England Journal of Medicine*. 2020.

7. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H and Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. *Cardiovascular diabetology*. 2014;13:148.

8. Kannel WB and McGee DL. Diabetes and cardiovascular disease: The framingham study. *JAMA*. 1979;241:2035-2038.

9. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S, Blankstein R and Di Carli MF. Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus. *Circulation*. 2012;126:1858-1868.

10. Levelt E, Rodgers CT, Clarke WT, Mahmood M, Ariga R, Francis JM, Liu A, Wijesundera RS, Dass S, Sabharwal N, Robson MD, Holloway CJ, Rider OJ, Clarke K, Karamitsos TD and Neubauer S. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. *European Heart Journal*. 2015.

11. Bratis K, Child N, Terrovitis J, Nanas J, Felekos I, Aggeli C, Stefanadis C, Mastorakos G, Chiribiri A, Nagel E and Mavrogeni S. Coronary microvascular dysfunction in overt diabetic cardiomyopathy. *IJC Metabolic & Endocrine*. 2014;5:19-23.

12. Larghat AM, Swoboda PP, Biglands JD, Kearney MT, Greenwood JP and Plein S. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study, 2014.

13. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. *The American journal of cardiology*. 1972;30:595-602.

14. Swoboda PP, McDiarmid AK, Erhayiem B, Ripley DP, Dobson LE, Garg P, Musa TA, Witte KK, Kearney MT, Barth JH, Ajjan R, Greenwood JP and Plein S. Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. *Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease*. 2017;6:e005539.

15. Wong TC, Piehler KM, Kang IA, Kadakkal A, Killman P, Schwartzman DS, Mulukutla SR, Simon MA, Shroff SG, Kuller LH and Schelbert EB. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. *European heart journal*. 2014;35:657.

16. Asbun J and Villarreal FJ. The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy. *Journal of the American College of Cardiology*. 2006;47:693-700.

17. Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S and Di Tullio MR. Association Between Diabetes Mellitus and Left Ventricular Hypertrophy in a Multiethnic Population. *The American Journal of Cardiology*. 2008;101:1787-1791.
18. Taskiran M, Fritz-Hansen T, Rasmussen V, Larsson HBW and Hilsted J. Decreased Myocardial Perfusion Reserve in Diabetic Autonomic Neuropathy. *Diabetes*. 2002;51:3306-3310.

19. Marwick CLJWSJWCJBHLJMJTH. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. *European Heart Journal - Cardiovascular Imaging*. 2014;15:776–786.

20. Gulati A, Japp AG, Raza S, Halliday BP, Jones DA, Newsome S, Ismail NA, Morarji K, Khwaja J, Spath N, Shakespeare C, Kalra PR, Lloyd G, Mathur A, Cledan JGF, Cowie MR, Assomull RG, Pennell DJ, Ismail TF and Prasad SK. Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. *Circulation: Cardiovascular Imaging*. 2018;11.

21. Rubinshtein R, Yang EH, Rihal CS, Prasad A, Lennon RJ, Best PJ, Lerman LO and Lerman A. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. *European Heart Journal*. 2009;31:936-942.

22. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD and Kelly DP. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. *J Clin Invest*. 2002;109:121-130.

23. Gulick T, Cresci S, Caira T, Moore DD and Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. *Proc Natl Acad Sci U S A*. 1994;91:11012-6.

24. Leone TC, Weinheimer CJ and Kelly DP. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. *Proceedings of the National Academy of Sciences*. 1999;96:7473-7478.

25. Wu P, Inskeep K, Bowker-Kinley MM, Popov KM and Harris RA. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. *Diabetes*. 1999;48:1593.

26. Stanley WC, Lopaschuk GD and McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. *Cardiovascular Research*. 1997;34:25-33.

27. Jia G, Hill Michael A and Sowers James R. Diabetic Cardiomyopathy. *Circulation Research*. 2018;122:624-638.

28. Hudsmith LE, Petersen SE, Tyler DJ, Francis JM, Cheng AS, Clarke K, Selvanayagam JB, Robson MD and Neubauer S. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study. *J Magn Reson Imaging*. 2006;24:312-8.

29. Gulsin GS, Swarbrick DJ, Hunt WH, Levelt E, Graham-Brown MPM, Parke KS, Wormleighton JV, Lai FY, Yates T, Wilmot EG, Webb DR, Davies MJ and McCann GP. Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. *Diabetes*. 2018;67:1395.

30. Levelt E, Mahmud M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, Clarke K, Rider OJ and Neubauer S. Relationship between Left Ventricular Structural and Metabolic Remodelling in Type 2 Diabetes Mellitus. *Diabetes*. 2015.
31. Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL and Folsom AR. The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events: The MESA Study. *Journal of the American College of Cardiology*. 2008;52:2148-2155.

32. Khan JN, Wilmot EG, Leggate M, Singh A, Yates T, Nimmo M, Khunti K, Horsfield MA, Biglands J and Clarysse P. Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms. *Eur Heart J Cardiovasc Imaging*. 2014;15.

33. Ernande L, Rietzschel ER, Bergerot C, De Buyzere ML, Schnell F, Groisne L, Ovize M, Croisille P, Moulin P, Gillebert TC and Derumeaux G. Impaired Myocardial Radial Function in Asymptomatic Patients with Type 2 Diabetes Mellitus: A Speckle-Tracking Imaging Study. *Journal of the American Society of Echocardiography*. 2010;23:1266-1272.

34. Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, Clarke W, Sabharwal N, Antoniades C, Schneider J, Robson M, Clarke K, Karamitsos T, Rider O and Neubauer S. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. *Journal of the American College of Cardiology*. 2016;68:53-63.

35. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE and Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373.

36. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P and Rayman G. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. *Diabetes Therapy*. 2017;8:55-73.

37. Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L and Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. *Cardiovascular diabetology*. 2017;16:138-138.

38. Kang S, Verma S, Teng G, Belke D, Svystonyuk D, Guzzardi D, Park D, Turnbull J, Malik G and Fedak P. DIRECT EFFECTS OF EMPAGLIFLOZIN ON EXTRACELLULAR MATRIX REMODELING IN HUMAN CARDIAC FIBROBLASTS: NOVEL TRANSLATIONAL CLUES TO EMPA-REG OUTCOME. *Canadian Journal of Cardiology*. 2017;33:S169.

39. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J and Korn S. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373.

40. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC and Zannad F. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2013;369:1327-1335.

41. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M and Xue H. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. *Journal of Cardiovascular Magnetic Resonance*. 2017;19:43.
42. Karamitsos T, Hudsmith L, Selvanayagam J, Neubauer S and Francis J. Operator induced variability in left ventricular measurements with cardiovascular magnetic resonance is improved after training. *J Cardiovasc Magn Reson.* 2007;777-783.

43. Ugander M, Oki AJ, Hsu L-Y, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP and Arai AE. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. *European Heart Journal.* 2012;33:1268-1278.

44. Swoboda PA-O, Erhayiem B, Kan R, McDiarmid AK, Garg P, Musa TA, Dobson LE, Witte KK, Kearney MT, Barth JH, Ajjan R, Greenwood JP and Plein S. Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes.

45. Von Scholten BJ, Hasbak P, Christensen TE, Ghotbi AA, Kjaer A, Rossing P and Hansen TW. Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. *Diabetologia.* 2016;59:371-378.

46. Verma S, McMurray JJV and Cherney DZI. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure Metabolodiuretic Promise of SGLT2 Inhibition Metabolodiuretic Promise of SGLT2 Inhibition. *JAMA Cardiology.* 2017;2:939-940.

47. Sattar N, McLaren J, Kristensen SL, Preiss D and McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? *Diabetologia.* 2016;59:1333-1339.

48. Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, Linz P, Nagel AM, Titze J, Uder M and Schmieder RE. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. *Cardiovascular diabetology.* 2018;17:5-5.

49. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR and Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. *Diabetes.* 2016;65:1190-5.

50. Mudaliar S, Alloju S and Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. *Diabetes Care.* 2016;39:1115-22.

51. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B and Connelly KA. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. *Circulation.* 2019;140:1693-1702.

**Figures**
Figure 1

Potential molecular and macroscopic pathophysiological mechanisms leading to cardiac dysfunction in type 2 diabetes. In diabetes, insulin fails to suppress hormone sensitive lipase secretion in adipose tissue and very low-density lipoprotein secretion in the liver, leading to high circulating fatty acids. When fatty acid availability exceeds fatty acid oxidation rates, intramyocardial lipids accumulate. The subsequent lipotoxicity plays a role in the development of contractile dysfunction and observed in the diabetic heart. Moreover, inhibition of pyruvate dehydrogenase (due to the effects of pyruvate dehydrogenase kinase 4 induction and fatty acid derived acetyl-CoA) limits pyruvate oxidation. The dissociation of glycolysis and pyruvate oxidation in the diabetic heart results in the accumulation of glycolytic intermediates and glucotoxicity. Hyperglycemia, insulin resistance, and hyperinsulinemia induce cardiac insulin resistance and metabolic disorders leading to mitochondrial dysfunction, oxidative stress, advanced glycation end products (AGEs), impairment of mitochondrial Ca2+ handling, inflammation, activation of renin–angiotensin–aldosterone system (RAAS), autonomic neuropathy, apoptosis, and endothelial dysfunction. These pathophysiological abnormalities promote cardiac stiffness, hypertrophy, coronary microvascular dysfunction and fibrosis, resulting in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. Figure adapted from Jia et al.
Study flow chart. Screening (Visits 1 and 2): Screening assessments will be performed over two visits and will include a review of medical history and concomitant medications, and a review of history of diabetes and complications. Screening tests will include blood tests for fasting serum glucose, insulin, full blood count (FBC), urea and electrolytes (U&E), glycated haemoglobin (HbA1c). The most recent clinical echocardiography report will be reviewed, and the Libre Pro Sensor fitting will be performed at this visit.
Visit 3: First CMR assessments will be scheduled for the 3rd study visit to the research centre (at least 2 months after myocardial infarction, revascularisation procedure or unstable angina episode). Prior to CMR imaging the Libre Pro Sensor will be removed and randomisation to one of the two medications will be undertaken. Visit 4: Blood tests including fasting serum glucose, insulin, FBC, U&E, and HbA1c will be performed and a second Libre Pro Sensor will be fitted. Visit 5: The Libre Pro Sensor will be removed and the second CMR scan will be undertaken. Visit 6: Further blood tests including fasting serum glucose, insulin, FBC, U&E, and HbA1 will be performed and the final Libre Pro Sensor will be fitted. Visit 7 (Final Visit): The Libre Pro Sensor will be removed and the final CMR scan will be performed.

Figure 3

CMR protocol. LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular; SA, short axis.